ANAHEIM, CA — November 18, 2025 — Leads & Copy — BioCorRx Inc. (OTCQB: BICX) reported increased revenue and a reduced net loss for the third quarter ended September 30, 2025, according to a press release issued today.
Revenue for Q3 2025 increased to $635,224, compared to $0 for Q3 2024. The company also reported a reduced net loss of $808,502 in Q3 2025, down from $1.5 million in Q3 2024.
The revenue increase was driven primarily by supply and distribution sales of LUCEMYRA®, an FDA-approved opioid withdrawal medication, under BioCorRx Pharmaceuticals Inc., a wholly-owned subsidiary. The company reported its second consecutive quarter of revenue following the acquisition of LUCEMYRA®.
Revenue for the nine months ended September 30, 2025, increased to $948,362 from $7,665 in the prior-year period, also driven by LUCEMYRA®-related sales.
BioCorRx is also developing BICX104 for opioid and alcohol use disorders under BioCorRx Pharmaceuticals Inc. The company anticipates commencing clinical studies supported by a grant from the National Institute on Drug Abuse (NIDA).
In March 2024, BioCorRx was awarded an $11 million, multi-year grant from NIDA to support the clinical development of BICX104, a long-acting, sustained-release naltrexone implant candidate.
The company anticipates providing updates as the BICX104 program progresses and remains encouraged by the strength of completed work and the potential clinical utility of BICX104 for opioid use disorder (OUD) and alcohol use disorder (AUD).
BioCorRx remains focused on expanding access to LUCEMYRA®, enhancing operational efficiencies, and advancing its pipeline programs addressing substance use disorders through its subsidiary BioCorRx Pharmaceuticals Inc.
The company has begun discussions related to potential debt restructuring initiatives and expects to provide updates as appropriate.
A copy of the Company’s quarterly report on Form 10-Q for the third quarter ended September 30, 2025, has been filed with the Securities and Exchange Commission and posted on the Company’s website.
According to the release, Lourdes Felix, CEO, CFO and Director of BioCorRx Inc. said the results reflect steady and meaningful revenue generation following the acquisition of LUCEMYRA® earlier this year and added that revenues are now material, and the company believes it is positioned to continue building on this foundation as it expands its commercial footprint.
To report SUSPECTED ADVERSE REACTIONS or product complaints, contact BioCorRx Pharmaceuticals Inc. at 1-833-LUCEMYRA.
BioCorRx Inc. can be contacted at info@BioCorRx.com or 714-462-4880.
Investor Relations can be contacted through Crescendo Communications, LLC at 212- 671-1020 x304 or bicx@crescendo-ir.com
Source: BioCorRx Inc.
